



## **Hercules Realizes Gross Proceeds of Approximately \$743,000 on Sale of Common Stock Warrants in Omrix Biopharmaceuticals, Inc.**

**Palo Alto, Calif. - Dec. 5, 2006**— Hercules Technology Growth Capital, Inc. (NASDAQ: HTGC), a leading specialty finance company providing debt and equity growth capital to venture capital and private equity backed technology and life science companies, announced today that it has completed the sale of common stock acquired upon exercise of a warrant for shares of Omrix Biopharmaceuticals, Inc. (NASDAQ: OMRI), a commercial-stage biopharmaceutical company that develops and markets biosurgical and antibody-based products. The sale of the common stock was completed during November 2006 and, accordingly, Hercules received gross proceeds of approximately \$743,000, representing an IRR in excess of 30% on the total investment.

### **About Hercules Technology Growth Capital, Inc.:**

Founded in December 2003, Hercules Technology Growth Capital, Inc. is a NASDAQ traded specialty finance company providing debt and equity growth capital to technology-related companies at all stages of development. The Company primarily finances privately-held companies backed by leading venture capital and private equity firms and also may finance certain publicly-traded companies. Hercules' strategy is to evaluate and invest in a broad range of ventures active in technology and life science industries and to offer a full suite of growth capital products up and down the capital structure to prospective clients ranging from early-stage growth to expansion stage companies. The Company's investments are originated through its principal office located in Silicon Valley, as well as additional offices in the Boston, Boulder and Chicago areas. Providing capital to publicly-traded or privately-held companies backed by leading venture capital and private equity firms involves a high degree of credit risk and may result in potential losses of capital.

For more information, please visit [www.HerculesTech.com](http://www.HerculesTech.com), or [www.HTGC.com](http://www.HTGC.com). Companies interested in learning more about financing opportunities should contact [info@HTGC.com](mailto:info@HTGC.com), or call 650.289.3060.

### **Forward-Looking Statements:**

The statements contained in this release that are not purely historical are forward-looking statements. These forward-looking statements are not guarantees of future performance and are subject to uncertainties and other factors that could cause actual results to differ materially from those expressed in the forward-looking statements including, without limitation, the risks, uncertainties and other factors we identify from time to time in our filings with the Securities and Exchange Commission. Although we believe that the assumptions on which these forward-looking statements are reasonable, any of those assumptions could prove to be inaccurate and, as a result, the forward-looking statements based on those assumptions also could be incorrect. You should not place undue

reliance on these forward-looking statements. The forward-looking statements contained in this release are made as of the date hereof, and Hercules assumes no obligation to update the forward-looking statements for subsequent events.

---

**Contact:**

Hercules Technology Growth Capital, Inc.  
Main, 650.289.3060  
[info@herculestech.com](mailto:info@herculestech.com)  
David Lund (650) 289-3077  
[dlund@herculestech.com](mailto:dlund@herculestech.com)